<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01232205</url>
  </required_header>
  <id_info>
    <org_study_id>asip02</org_study_id>
    <nct_id>NCT01232205</nct_id>
  </id_info>
  <brief_title>Antioxidant Supplementation in Pregnant Women</brief_title>
  <acronym>ASIP1</acronym>
  <official_title>Antioxidant Supplementation in Pregnant Women With Low Antioxidant Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Showa University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Showa University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the benefit of several micro nutrients of
      antioxidants (using milk) in a cohort of women with low antioxidant status and the changes in
      cell-free mRNA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preeclampsia remains one of leading causes of maternal and perinatal mortality and morbidity.
      Despite intensive research, the cause of preeclampsia has not been established. One of the
      theories is exaggeration of systemic inflammatory that might induce reactive oxygen species
      (ROS). It has been proposed that pregnancy will progress uneventfully if adequate antioxidant
      exists to buffer ROS. The ROS can induce endothelial dysfunction which leads to clinical
      symptoms of hypertension and proteinuria in preeclampsia. Several large randomized clinical
      trials of antioxidant supplementation have concluded that there were no benefits of
      antioxidants supplementation for prevention of preeclampsia. However, there is limited
      information about benefits of antioxidants in women with low antioxidant status at early
      gestation that deprived of the antioxidant most. Our aim, therefore, in this study was to
      assess whether early supplementation with milk enriched with vitamin and mineral, such as Cu,
      Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium lowers the risk of
      preeclampsia in women with low antioxidant status at early gestation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>40 weeks</time_frame>
    <description>Preeclampsia was defined as gestational hypertension (systolic pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg [Korotkoff V] on ≥ 2 occasions after 20 weeks gestation) with proteinuria (&gt; 0.3 g/day). Severe preeclampsia was defined by the presence of &gt;1 of the following: (a) severe gestational hypertension (systolic pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg on 2 occasions after gestational week 20), or (b) severe proteinuria (≥5g protein in a 24-h urine specimen or ≥3 g in 2 random urine samples collected ≥4 h apart)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preeclampsia</measure>
    <time_frame>9 months</time_frame>
    <description>Preeclampsia was defined as gestational hypertension (systolic pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg [Korotkoff V] on ≥ 2 occasions after 20 weeks gestation) with proteinuria (&gt; 0.3 g/day). Severe preeclampsia was defined by the presence of &gt;1 of the following: (a) severe gestational hypertension (systolic pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg on 2 occasions after gestational week 20), or (b) severe proteinuria (≥5g protein in a 24-h urine specimen or ≥3 g in 2 random urine samples collected ≥4 h apart)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cell-free mRNA</measure>
    <time_frame>40 weeks</time_frame>
    <description>Secondary outcome were level of mRNA level of angiogenic factors (vascular endothelial growth factor receptor-1 (VEGFR-1), placental growth factor (PlGF) and endoglin(ENG)); antioxidant status (FRAP, heme oksigenase-1 (HO-1) and superoxide-dismutase (SOD))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Pregnant Women</condition>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>micronutrient antioxidant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>micronutrient antioxidant</intervention_name>
    <description>Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium</description>
    <arm_group_label>micronutrient antioxidant</arm_group_label>
    <other_name>antioxidant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>supplementation with milk</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women with 8-12 weeks of gestation

        Exclusion Criteria:

          -  known multiple pregnancy

          -  known fetal anomaly

          -  known thrombophilia

          -  known infections and mola hydatidosa

          -  chronic renal failure

          -  uncontrolled hypertension

          -  known placental abnormalities

          -  documented uterine bleeding within a week of screening

          -  uterine malformation

          -  history of medical and metabolic complication such as heart disease or diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noroyono Wibowo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dept Obstetrics Gynecology, Indonesia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuditiya Purwosunu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Obstetrics Gynecology Indonesia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cipto Mangunkusumo National Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>13210</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2010</study_first_posted>
  <results_first_submitted>November 2, 2010</results_first_submitted>
  <results_first_submitted_qc>November 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2010</results_first_posted>
  <last_update_submitted>November 2, 2010</last_update_submitted>
  <last_update_submitted_qc>November 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yuditiya Purwosunu</name_title>
    <organization>Dept Obstetrics Gynecology, Indonesia University</organization>
  </responsible_party>
  <keyword>antioxidant supplementation</keyword>
  <keyword>preeclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Micronutrients</mesh_term>
    <mesh_term>Trace Elements</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in June 2001 and completed in December 2009, Department of Obstetrics and Gynaecology, University of Indonesia, at Cipto Mangunkusumo National Hospital</recruitment_details>
      <pre_assignment_details>There were 110 (65.4 percent) eligible subjects from 168 pregnant women, because of ferric reducing ability of plasma (FRAP) level measured</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Micronutrient Antioxidant</title>
          <description>Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Micronutrient Antioxidant</title>
          <description>Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="5.08"/>
                    <measurement group_id="B2" value="29.7" spread="5.07"/>
                    <measurement group_id="B3" value="28.9" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Indonesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Preeclampsia</title>
        <description>Preeclampsia was defined as gestational hypertension (systolic pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg [Korotkoff V] on ≥ 2 occasions after 20 weeks gestation) with proteinuria (&gt; 0.3 g/day). Severe preeclampsia was defined by the presence of &gt;1 of the following: (a) severe gestational hypertension (systolic pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg on 2 occasions after gestational week 20), or (b) severe proteinuria (≥5g protein in a 24-h urine specimen or ≥3 g in 2 random urine samples collected ≥4 h apart)</description>
        <time_frame>40 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cell-free mRNA</title>
        <description>Secondary outcome were level of mRNA level of angiogenic factors (vascular endothelial growth factor receptor-1 (VEGFR-1), placental growth factor (PlGF) and endoglin(ENG)); antioxidant status (FRAP, heme oksigenase-1 (HO-1) and superoxide-dismutase (SOD))</description>
        <time_frame>40 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Preeclampsia</title>
        <description>Preeclampsia was defined as gestational hypertension (systolic pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg [Korotkoff V] on ≥ 2 occasions after 20 weeks gestation) with proteinuria (&gt; 0.3 g/day). Severe preeclampsia was defined by the presence of &gt;1 of the following: (a) severe gestational hypertension (systolic pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg on 2 occasions after gestational week 20), or (b) severe proteinuria (≥5g protein in a 24-h urine specimen or ≥3 g in 2 random urine samples collected ≥4 h apart)</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Micronutrient Antioxidant</title>
            <description>Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Preeclampsia</title>
          <description>Preeclampsia was defined as gestational hypertension (systolic pressure ≥140 mmHg or diastolic blood pressure ≥ 90 mmHg [Korotkoff V] on ≥ 2 occasions after 20 weeks gestation) with proteinuria (&gt; 0.3 g/day). Severe preeclampsia was defined by the presence of &gt;1 of the following: (a) severe gestational hypertension (systolic pressure ≥160 mmHg or diastolic blood pressure ≥110 mmHg on 2 occasions after gestational week 20), or (b) severe proteinuria (≥5g protein in a 24-h urine specimen or ≥3 g in 2 random urine samples collected ≥4 h apart)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>nine months</time_frame>
      <desc>monthly questionare</desc>
      <group_list>
        <group group_id="E1">
          <title>Micronutrient Antioxidant</title>
          <description>Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yuditiya Purwosunu</name_or_title>
      <organization>Dept Obstetrics Gynecology Indonesia University</organization>
      <phone>+44 753 870 6897</phone>
      <email>yudi@med.showa-u.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

